Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
16.45
-0.05 (-0.30%)
Apr 29, 2026, 12:32 PM EDT - Market open
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
29.33M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% |
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| IGC Pharma | 70 |
| Senti Biosciences Holdings | 34 |
| Kyntra Bio | 34 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Apollomics | 13 |
PLRZ News
- 2 days ago - Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform - GlobeNewsWire
- 20 days ago - Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements - GlobeNewsWire
- 4 weeks ago - Polyrizon Provides 2025 and Recent Highlights - GlobeNewsWire
- 4 weeks ago - Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - GlobeNewsWire
- 5 weeks ago - Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications - GlobeNewsWire
- 6 weeks ago - Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program - GlobeNewsWire
- 7 weeks ago - Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - GlobeNewsWire
- 2 months ago - Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product - GlobeNewsWire